Ipsen will be launching a new pre-filled syringe for its blockbuster rare disease drug Somatuline (lanreotide) in the EU. The new design was based on several studies, involving patients ...
Ipsen is offering $1.45 per share for Cambridge ... sales for top-selling acromegaly and neuroendocrine tumour therapy Somatuline (lanreotide). Tazverik is a first-in-class EZH2a inhibitor ...
Afinitor plus Somatuline significantly improved PFS in GEP-NETs compared to Afinitor monotherapy, with median PFS of 29.7 vs. 11.5 months. The combination therapy showed a higher objective response ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback